Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 3Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1Carcinoma 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Terminated × futuximab × Clear all
NCT03549338 2020-09-28

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

Symphogen A/S

Phase 2 Terminated
2 enrolled 9 charts
Gastrointestinal

Carcinoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡